Identification of Amplification Loop between Mitochondrial Mutation and Oxidative Stress; Seeking to Overcome Intractable Metabolic Diseases via Cell Models and Gene Editing
Background
Mitochondria, intracellular organelles, produce most of the adenosine triphosphate (ATP) required for life through oxidative phosphorylation (OXPHOS). Simultaneously, they are a primary source of reactive oxygen species (ROS), which cause cellular damage due to inevitable electron leakage during the cellular respiration process. Mitochondrial DNA (mtDNA) forms an independent circular structure and follows maternal inheritance; unlike the nuclear genome, it lacks a histone protein shield and has weak repair mechanisms, leading to a much higher frequency of mutations.
A key challenge hindering the development of treatments for mitochondrial diseases is genetic complexity. The state where normal mtDNA and mutant mtDNA coexist within a cell is called heteroplasmy. The proportion of mutant alleles varies by tissue, and pathological symptoms manifest only when a specific clinical threshold is exceeded. Even for patients with the same genetic abnormality, the extent and severity of symptoms vary significantly across high-energy-consuming organs such as the central nervous system, skeletal muscle, and heart. Previous studies relied on random tissue biopsies or post-mortem analysis, making it difficult to identify precise causal relationships in disease progression, and the development of disease-specific therapeutics has remained at a standstill.
Key Findings
This study clearly identified the vicious cycle in which structural defects in the electron transport chain (ETC) complexes and oxidative stress work together. When electron flow stagnates due to mutations in complex components, abnormal electron leakage surges, releasing massive amounts of ROS. The accumulated reactive oxygen species not only induce additional mutations in adjacent mtDNA but also trigger a 'snowballing effect' that sequentially destroys cardiolipin, lipids, and metabolic regulatory proteins in the inner membrane. The researchers performed a molecular-level comparative analysis of the energy deficiency patterns observed in the m.3243A>G mutation of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and the m.8344A>G mutation of myoclonic epilepsy with ragged red fibers (MERRF).
The foundation that enabled this pathological analysis is the advancement of patient-specific cell model systems. The research team differentiated patient-derived induced pluripotent stem cells (iPSCs) into neurons and cardiomyocytes to reproduce tissue-specific metabolic phenotypes. Additionally, to completely exclude nuclear genome variables and evaluate the independent impact of mtDNA variants alone, they also applied the transmitochondrial cybrid technique. This achievement involved the quantitative measurement of decreased electron transport chain (ETC) activity and mitochondrial membrane potential in accordance with mutation ratios within a standardized nuclear background. Furthermore, they verified the effectiveness of a gene control strategy to lower the mutation ratio below the clinical threshold using cytosine base editors (DdCBE), which fuse mitochondrial-targeted transcription activator-like effector nucleases (mitoTALENs) with bacterial-derived cytosine deaminase.
Significance and Outlook
The results of clarifying the molecular mechanisms of the disease based on cell models and confirming the applicability of precision gene editing technology provide a clue to shift the treatment paradigm for mitochondrial genetic diseases from symptom alleviation to cause correction. The approach of inducing heteroplasmy ratios to normal levels is evaluated as a therapeutic breakthrough that can preemptively block irreversible neurodegeneration and muscle damage. Utilizing patient-derived iPSC models in the drug candidate discovery process allows for high-accuracy prediction of efficacy and metabolic toxicity before entering clinical trials.
There are still challenges to be overcome for realistic commercialization. A drug delivery system (DDS) technology must be established to efficiently deliver editing enzymes across the mitochondrial double membrane to target tissues in vivo. The diversity of signaling exchanges between the nuclear genome and the mitochondrial genome within the patient's body is also considered a variable. Large-scale validation studies using animal models must follow to minimize off-target effects that cause unintended mutations in non-target mtDNA sequences and to ensure long-term safety.
Mitochondria are essential structures that produce energy in cells through mitochondrial oxidative phosphorylation and are one of the primary sources of reactive oxygen species (ROS). Mutations in mitochondrial DNA (mtDNA) cause a wide range of hereditary illnesses with multisystem clinical symptoms, poor cellular bioenergetics, and decreased mitochondrial oxidative phosphorylation. Effective treatment approaches have been hampered by the genetic complexity associated with mtDNA disorders, including heteroplasmy and tissue-specific diversity. The relationship between mutations in the mitochondrial DNA and oxidative stress is multidimensional and snowballing, with structural malfunction of the electron transport chain encouraging the development of ROS that causes further damage to mitochondrial DNA, lipids, and proteins. Under carefully regulated experimental conditions, cell-based disease models, in particular induced pluripotent stem cells (iPSCs) and standard transmitochondrial cybrids, have become useful tools for studying disease mechanisms, simulating mutation-specific phenotypes, and assessing possible therapeutic interventions. This review provides the key roles of mutations and oxidative stress in the pathogenesis of the disease in the context of the primary role of the mitochondrial genome, its maternal inheritance, and the most common disorders, i.e., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and myoclonic epilepsy with ragged red fibers (MERRF). We outline the use of cell-based models to study mitochondrial pathologies, including patient-derived primary cells and iPSCs, which could be differentiated into cell types of interest to the disease, and cybrid systems, which could isolate the contribution of single mutations in the mitochondrial DNA to an underlying background of controlled nuclear genetic backgrounds. Besides, the review focuses on innovative technologies to mend mutations in mitochondrial DNA, such as
The cell-based disease model platform presented in this study can be immediately utilized to establish a customized screening environment for patients with mitochondrial diseases. By generating iPSCs from a patient's skin fibroblasts or blood cells without invasive muscle biopsies and differentiating them into neurons, antioxidant combination therapies or metabolic activators optimized for each patient's mutation burden can be tested in advance. From the perspective of the pharmaceutical industry, it can be expanded into a high-throughput screening system to early detection of mitochondrial toxicity that is likely to occur in the early stages of drug development. As the precision of gene editing techniques improves, the development of next-generation gene and cell therapy pipelines to lower tissue-specific heteroplasmy in patients with severe genetic metabolic diseases below the disease expression threshold is also expected to accelerate.